EUCTR2010-023552-90-AT进行中（未招募）1 期
Short-term endothelin A receptor blockade in patients with on-pump coronary artery bypass grafting - BQ-123 in CABG
Medizinische Universität Wien, Abteilung für Herzchirurgie0 个研究点目标入组 36 人开始时间: 2010年12月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients undergoing on-pump coronary artery bypass grafting using the left mammary artery to the left anterior descendent artery and at least one vein graft due to coronary artery disease, aged 18 years and above.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Significant liver disease (Transaminases and gamma-GT > 3 fold upper limit)
- •Glomerular filtration rate <40mL/h
- •History of severe congestive heart failure (Left ventricular ejection fraction <40%)
- •Current atrial fibrillation
- •Significant valvular heart disease requiring valve reconstruction or replacement
- •Primary myocardial disease
- •Acute coronary syndrome or cardiogenic shock (sRR <90mmHg or need for inotropic support)
- •Women with child-bearing potential
- •Inability to read, understand and sign the informed consent
- •Life expectancy <1y
- •Prior organ transplantation
- •Participation in a clinical trial using an investigational medical product
研究者
相似试验
进行中（未招募）
1 期
Efficacy of endothelin receptor antagonism in treatment of coronary artery spasm: a randomized controlled clinical trial. (EDIT-CAS)CTIS2023-507782-25-00Stichting Radboud University Medical Center100
进行中（未招募）
不适用
Effects of non-specific Endothelin-A receptor blockade on ocular blood flow in patients with glaucomapatients with primary open angle glaucoma in comparision to a healthy control group.EUCTR2006-003140-27-ATDepartment of Clinical Pharmacology28
进行中（未招募）
1 期
se of endothelin-1 antagonists in patients with Established Pulmonary Hypertension and Fibrotic Lung Disease. – A randomised, placebo-controlled, double-blinded study. - Tracleer in Interstitial Lung Disease and Pulmonary HypertensioPulmonary hypertension in patients with interstitial lung disease.MedDRA version: 9.1 Level: LLT Classification code 10064911 Term: Pulmonary arterial hypertensionEUCTR2007-001643-21-GBRoyal Brompton and Harefield NHS Trust48
进行中（未招募）
不适用
Endothelin antagonist trial in mildly symptomatic PAH patients. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of bosentan in patients with mildly symptomatic pulmonary arterial hypertension. - EARLYPatients with modified NYHA functional Class II PAH have mild symptoms, but their pulmonary artery pressures are elevated which leads to increased wall stress and silent heart damage progression. Therefore Class I-II patients have a better survival rate than Class III-IV patients (Odds ratio = 1.9) but will eventually deteriorate if untreated.MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2004-000478-30-DKActelion Pharmaceuticals Ltd.170
进行中（未招募）
不适用
Endothelin antagonist trial in mildly symptomatic PAH patients. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of bosentan in patients with mildly symptomatic pulmonary arterial hypertension. - EARLYPatients with modified NYHA functional Class II PAH have mild symptoms, but their pulmonary artery pressures are elevated which leads to increased wall stress and silent heart damage progression. Therefore Class I-II patients have a better survival rate than Class III-IV patients (Odds ratio = 1.9) but will eventually deteriorate if untreated.MedDRA version: 9.1Level: LLTClassification code 10064911Term: Pulmonary arterial hypertensionEUCTR2004-000478-30-BEActelion Pharmaceuticals Ltd.170